Clinical trials: HCM
Tumor, Cardiovascular Diseases
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
The purpose of this study is to conduct clinical research on [68Ga] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
- Conditions
- Tumor, Cardiovascular Diseases, Pulmonary Fibrosis, Rheumatic Immune Diseases Involving Large Blood Vessels
- Trial name
- NCT07464132
- Testing
- Injection of 68Ga-NI-FAPI
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Hypertrophic Cardiomyopathy
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results Number of subjects: 100 (including 10% dropout rate) Performance and safety were verified by…
- Trial name
- ATP-HCM (NCT06873828)
- Testing
- ATP-C135, ATP-C75
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Hypertrophic Cardiomyopathy
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
The main objective of the study is to improve implantable cardioverter defibrillator (ICD) implantation decision-making processing relevance by developing a new prediction model of sudden cardiac death (SCD) in hypertrophic…
- Trial name
- OPTIM-HCM (NCT03846297)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertrophic Cardiomyopathy (HCM)
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest.
- Trial name
- LA-HCM (NCT07202897)
- Testing
- Anticoagulant treatment Rivaroxaban, Best medical therapy
- Where
- 17 sites in France
- Volunteers
- 532 people
- Sponsor
- Rennes University Hospital
Fabry Disease
Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy
The purpose of this study was to assess the progression of cardiac involvement in adult patients with Fabry Disease (FD), in the unique Danish Fabry cohort and comparing those FD patients receiving primary therapy vs.
- Trial name
- NCT02908724
- Volunteers
- 66 people
- Sponsor
- Ulla Feldt-Rasmussen
Nonobstructive Hypertrophic Cardiomyopathy
ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
The primary objective of this study is to investigate the effect of enavogliflozin, an Sodium-glucose transporter 2 (SGLT2) inhibitor, compared with placebo on left ventricular diastolic function in patients with nonobstructive…
- Trial name
- NCT06580717
- Testing
- enavogliflozin 0.3mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Hypertrophic Cardiomyopathy
Study of Hypertrophic Cardiomyopathy Under Stress Conditions. Concordance Between Two Complementary Tests: Stress MRI and Exercice Stress Echocardiography
Hypertrophic cardiomyopathy (HCM) is a primitive myocardic disease and the first of genetic cardiac diseases. The definition of HCM is an increase of the myocardial thickness of the left ventricle (LV) wall without any other…
- Trial name
- CMHStress (NCT02500420)
- Testing
- Diagnosis examens
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Ventricular Arrythmia
China Structural Ventricular Arrhythmias Registry
This is an observational, prospective, multi-center registry ,aiming at building a risk stratification for malignant structural ventricular arrhythmias.
- Trial name
- NCT03821051
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hypertrophic Cardiomyopathy
VIZ ACCESS HCM - Multi-Site Registry
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM.
- Trial name
- NCT07103057
- Testing
- Viz HCM
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Viz.ai, Inc.
Hypertrophic Cardiomyopathy
Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function
The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
- Trial name
- NCT06775834
- Testing
- HRS-1893
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Cardiomyopathy, Hypertrophic
The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
This study will examine how heart stiffness and a weak atrium affect exercise capacity and symptoms in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT00074880
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Obstructive Cardiomyopathy
Mitral Valve in Hypertrophic Cardiomyopathy
The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical treatment modality to relieve…
- Trial name
- NCT03877731
- Testing
- isolated septal myectomy, septal myectomy + edge-to-edge mitral valve repair, septal myectomy + posterior leaflet sliding plasty
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy, Cardiac Sarcoidosis, Hypertensive Heart Disease
- Trial name
- CHIEFTain (NCT06409585)
- Testing
- 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
- Trial name
- NCT07383025
- Testing
- Mavacamten
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Cardiomegaly, Noonan Syndrome
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
- Trial name
- MEKinRAS (NCT06555237)
- Testing
- Trametinib tablet, Standard therapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Medical University of Warsaw
Hypertrophic Cardiomyopathy
Extended Ambulatory Monitoring Improves Risk Stratification in Hypertrophic Cardiomyopathy
Eligible subjects will wear 4 consecutive external monitoring devices for a total of 28 days of monitoring.
- Trial name
- NCT03182153
- Testing
- Extended Cardiac Monitoring
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Atlantic Health System
Hypertrophic Cardiomyopathy (HCM)
Individualized Exercise Training in Hypertrophic Cardiomyopathy
Exercise intervention trials in patients with hypertrophic cardiomyopathy (HCM) have demonstrated an association with improvement in resting and exercise hemodynamics, ventricular remodeling, and anxiety/depression.
- Trial name
- GET-FIT HCM (NCT07835854)
- Testing
- Exercise Intervention, Physical Activity Handout
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001871
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
The aim of this study is to assess microvascular function as determined by a cardiovascular magnetic resonance measurement of whole-heart (global) perfusion reserve.
- Conditions
- Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
- Trial name
- NCT03249272
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Cardiovascular Disease
The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study
This study proposes to describe how children s hypertrophic cardiomyopathy (HCM) risk status affects family functioning, behaviors, and relationships. HCM is the most common inherited cardiovascular single-gene disorder.
- Trial name
- NCT01160536
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Human Genome Research Institute (NHGRI)